Apyx Medical (APYX) CFO awarded 132,066 stock options at $4.65

Rhea-AI Filing Summary

Apyx Medical Corp reported that Chief Financial Officer Matthew C. Hill received a grant of stock options as part of his compensation. The award covers 132,066 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, these options vest ratably over a thirty-six month period and become fully vested and exercisable on the third anniversary of the grant date. Following this grant, Hill holds 132,066 stock options directly, and the filing shows no open-market purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HILL MATTHEW C

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Option to Buy)	132,066	$0.00	--

Holdings After Transaction: Stock Option (Option to Buy) — 132,066 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 132,066 options Exercise price: $4.65 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options granted 132,066 options Stock Option grant to CFO on June 11, 2026

Exercise price $4.65 per share Conversion or exercise price of granted options

Expiration date June 11, 2036 Option expiration for CFO grant

Underlying shares 132,066 shares Common stock underlying granted options

Post-grant option holdings 132,066 options Total stock options held following transaction

Vesting period 36 months Options vest ratably and fully vest on third anniversary

Key Terms

Stock Option (Option to Buy), conversion or exercise price, vest ratably, Grant, award, or other acquisition

4 terms

Stock Option (Option to Buy) financial

"security_title: "Stock Option (Option to Buy)" granted to the CFO"

conversion or exercise price financial

"conversion_or_exercise_price: "4.6500" per share for the option grant"

vest ratably financial

"option "shall vest ratably over a thirty six (36) month period""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HILL MATTHEW C

(Last) (First) (Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER FLORIDA 33760

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Option to Buy)	$4.65	06/11/2026		A		132,066		(1)	06/11/2036	Common Stock	132,066	$0	132,066	D

Explanation of Responses:

1. Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.

	/s/ Matthew C. Hill	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Apyx Medical (APYX) disclose about CFO Matthew Hill in this Form 4?

Apyx Medical disclosed that CFO Matthew C. Hill received a grant of 132,066 stock options. These options are part of his compensation package and give him the right to buy common shares at a fixed exercise price in the future.

How many stock options did the Apyx Medical CFO receive in the latest filing?

The CFO received 132,066 stock options linked to Apyx Medical common stock. All 132,066 options are shown as directly owned following the grant, indicating this award establishes his current reported option position in the filing.

What is the exercise price and term of the Apyx Medical CFO’s new options?

The granted stock options have an exercise price of $4.65 per share and expire on June 11, 2036. This means the CFO can choose to exercise the options at that price any time before the stated expiration date, once vested.

How do the Apyx Medical CFO’s options vest over time?

The options vest ratably over a thirty-six month period and become fully vested on the third anniversary of the grant date. This schedule gradually delivers ownership rights, aligning the CFO’s incentives with the company’s performance over several years.

Does the Apyx Medical Form 4 show any stock purchases or sales by the CFO?

The Form 4 shows a grant of stock options coded as a grant, award, or other acquisition, not an open-market trade. It does not report any stock purchases or sales, only the new option award and resulting holdings.